Attomarker

About:

Attomarker is a hand-held blood testing device that can perform up to 8 tests from a pin-prick of blood, delivering results in 5 minutes.

Website: http://www.attomarker.com/

Twitter/X: attomarker

Top Investors: Future Planet Capital, The British Innovation Fund

Description:

Attomarker is a spin-out company from the University of Exeter, a member of the UK’s Russell Group of research-intensive universities. The company’s founder, Professor Andrew Shaw, leads a team of scientists and engineers across the UK & Germany. Backed by six patents and referenced in 17 academic journals, Attomarker works. Realising the vision that has inspired many, but has, until now, proved so hard to turn into reality. Patented Attomarker technology collects the blood on a disposable credit-card sized chip which slots into a mobile pocket-sized devise, docked to an iPhone. The camera visualises the blood tests which are then interpreted by the iPhone. Test results can be shared, linked to electronic patient record systems and an AI Symptom checker for diagnosis. A tele-consultation will be available via the phone. Planned launch tests include Food Allergy (covering the eight food allergens that account for 95% of all), Pregnancy (replacing unreliable and undignified urine tests) and C-reactive protein, the 21st C thermometer, (identifying infection faster than changes in temperature). Research projects that will follow include fifth generation HIV testing, infectious diseases such as Zika and Ebola, Alzheimer’s, immunotherapy cohort surveillance, sepsis and a vitamin panel test. Attomarker intends to develop three sales channels - private doctors, pharmacies and direct to consumer.